ROCKVILLE, Md.--(BUSINESS WIRE)--SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of diagnostics for neurological disorders and conditions, including Alzheimer’s disease (AD), is pleased to acknowledge Alzheimer’s & Brain Awareness Month in June as an opportunity to raise awareness about brain disorders including AD and other dementias as a major public health issue. DISCERN™ diagnostic test assesses the factors directly related to the formation of synaptic connections in the brain impacting loss of memory and cognition in people living with AD, as well as regulators of amyloid plaque and tau formation—hallmarks of AD at autopsy.
Dr. Rizzo, American Brain Coalition Board Chair says, “Early diagnosis of AD is key to risk reduction strategies to prevent or delay development of dementia, currently by modifying a person’s exposure to common risk factors. Disease-modifying agents capable of reversing initial pathological changes is an area of urgent research. Early Alzheimer's diagnosis provides an opportunity to participate in these clinical trials and, ultimately, a better chance of benefiting from treatment. The American Brain Coalition recognizes the importance of clinical trials and other treatments for the patients we serve.”
DISCERN, which has demonstrated 95% sensitivity and 95% specificity in the diagnosis and management of AD, combines three biomarkers: Morphometric Imaging to measure fibroblasts’ ability to form networks; Protein Kinase C ε to measure synaptic growth; and AD-Index to measure phosphorylation of Erk1 and Erk2 in response to bradykinin.
Frank Amato, CEO and president, SDx, says, “We recently presented clinical utility data demonstrating that most clinicians are not satisfied with the current diagnostic pathway and welcome a less subjective test, like DISCERN. With a more definitive test, like DISCERN, to inform their diagnosis, clinicians were more confident implementing their care plans for people with AD.”
About SYNAPS Dx
SYNAPS Dx is a privately held company focused on the research, development and commercialization of diagnostics for neurological disorders and conditions, including Alzheimer’s disease (AD). The Company offers DISCERN™, the first highly accurate, minimally invasive skin test supporting a clinician’s definitive diagnosis of AD versus other forms of dementia, even in early disease. SYNAPS Dx’s laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. Physicians and patients seeking more information can visit https://discerntest.com/. For more information on the Company, visit https://www.synapsdx.com/. Contact: info@synapsdx.com.
